MetaVia (MTVA) Cash from Investing Activities (2019 - 2024)
MetaVia's (MTVA) quarterly Cash from Investing Activities came in at -$3000.0 in Q2 2024, up 40.0% on a QoQ basis from -$5000.0 in Q1 2024.
MetaVia (MTVA) Cash from Investing Activities (2019 - 2024) Analysis & Trends
MetaVia (MTVA) has 5 years of Cash from Investing Activities data on file, last reported at -$3000.0 in Q2 2024.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$3000.0 in Q2 2024, while the trailing twelve-month figure through Sep 2025 was -$3000.0 (up 82.35% YoY) and the FY2025 annual result came in at -$2000.0, up 75.0% from the prior year.
- Cash from Investing Activities rose to -$3000.0 in Q2 2024, from -$5000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $71000.0 in Q4 2020 to a low of -$583000.0 in Q4 2021.
- A 4-year average of -$71500.0 and a median of -$4500.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2020 — Cash from Investing Activities soared 101.2% — and 2021, when it sank 921.13%.
- Tracing MTVA's Cash from Investing Activities over 4 years: stood at $71000.0 in 2020, then slumped by 921.13% to -$583000.0 in 2021, then surged by 98.46% to -$9000.0 in 2023, then soared by 66.67% to -$3000.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$3000.0 (Q2 2024), -$5000.0 (Q1 2024), and -$9000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | -37,000.00 |
| Sep 30, 2023 | -37,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2021 | -583,000.00 |
| Dec 31, 2021 | -583,000.00 |
| Dec 31, 2020 | 71,000.00 |
| Dec 31, 2020 | 71,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Dec 31, 2019 | -5.94 Mn |
| Dec 31, 2019 | -5.94 Mn |
| Sep 30, 2019 | -93,000.00 |
| Sep 30, 2019 | -93,000.00 |